Belgium-based Biocartis has officially launched its flagship molecular diagnostics system, Idylla. Together with Idylla, Biocartis also released its first oncology assay, the Idylla BRAF Mutation Test. Both Idylla and the Idylla BRAF Mutation Test have obtained CE-IVD marking.
According to company representatives, Idylla is a fully automated, real-time PCR system, and its access- on-demand design allows clinicians to initiate a new test at any time, without the need for batching or for trained operators. The system’s turnaround time is between 35 and 120 minutes. Idylla has a multiplex capability that offers the potential to detect up to 30 molecular targets simultaneously in the same sample, making the system very well suited for more complex assays.
The BRAF Mutation Test is Idylla’s first oncology test and is designed to determine the most appropriate treatment for a specific type of skin cancer. The assay can detect mutations directly from FFPE tissue slices in about 90 minutes, and the analytical sensitivity of the Idylla BRAF Mutation Test has been demonstrated during clinical performance studies. Biocartis is also working with Janssen Pharmaceutica and Abbott Molecular to develop a range of diagnostic tests in other disease areas.
Says Rudi Pauwels, Biocartis CEO and President: “We are convinced that Idylla will transform the day-to-day practice in molecular labs, making molecular testing more straightforward than ever imagined. This will significantly speed up the diagnostic process and will enable doctors to make therapy decisions in a much shorter time frame, ultimately improving treatment outcomes.” Learn more about Idylla.
Read more
